Pathogenesis of COVID19 and the applications of US FDA-approved repurposed antiviral drugs to combat SARS-CoV-2 in Saudi Arabia: A recent update by review of literature DOI Creative Commons
Almonther Abdullah Hershan

Saudi Journal of Biological Sciences, Journal Year: 2024, Volume and Issue: 31(7), P. 104023 - 104023

Published: May 11, 2024

Still, there is no cure for the highly contagious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-caused disease 2019 (COVID19). The COVID19 pandemic caused health emergencies which resulted in enormous medical and financial consequences worldwide including Saudi Arabia. Arabia largest Arab country of Middle East. urban setting makes it vulnerable towards SARS-CoV-2 (SCV-2). Religious areas this are visited by millions pilgrims every year Umrah Hajj pilgrimage, contributes to potential epidemic risk. throws various challenges healthcare professionals choose right drugs or therapy clinical settings because lack availability newer drugs. Current drug development discovery an expensive, complex, long process, involves a high failure rate trials. While repurposing United States Food Drug Administration (US FDA)-approved antiviral offers numerous benefits complete pharmacokinetic safety profiles, significantly shorten cycles reduce costs. A range repurposed US FDA-approved ribavirin, lopinavir/ritonavir combination, oseltamivir, darunavir, remdesivir, nirmatrelvir/ritonavir molnupiravir showed encouraging results trials treatment. In article, several COVID19-related discussions have been provided emerging variants concern of, pathogenesis, scenario Arabia, strategies against SCV-2, as well FDA‐approved that might be considered combat SCV-2 Moreover, context management along with its limitations future perspectives summarized.

Language: Английский

Non-antiviral therapies for viral infections: Harnessing host mechanisms DOI
Sruthi Sarvepalli,

Shubhadeepthi Vadarevu

International Immunopharmacology, Journal Year: 2025, Volume and Issue: 153, P. 114521 - 114521

Published: March 27, 2025

Language: Английский

Citations

0
Therapeutic Approaches for COVID-19: A Review of Antiviral Treatments, Immunotherapies, and Emerging Interventions DOI Creative Commons

Maria João Vidal Alves,

Ruana Carolina Cabral da Silva, Sérgio de Sá Leitão Paiva Júnior

et al.

Advances in Therapy, Journal Year: 2025, Volume and Issue: unknown

Published: May 8, 2025

The coronavirus disease 2019 (COVID-19) global health crisis, caused by the severe acute respiratory syndrome 2 (SARS-CoV-2), has presented unprecedented challenges to healthcare systems, leading rapid advances in treatment development. This review comprehensively examines current therapeutic approaches for managing COVID-19, including direct-acting antivirals, immunomodulators, anticoagulants, and adjuvant therapies, as well emerging experimental approaches. Direct-acting antivirals target various stages of viral life cycle, offering specific intervention points, while immunomodulators aim modulate host's immune response, reducing severity. Anticoagulant therapies address coagulopathy frequently observed cases, treatments provide supportive care improve overall outcomes. We also explore limitations implementing these treatments, such drug resistance, variable patient responses, access especially resource-limited settings. discusses future perspectives, potential next-generation vaccines, personalized medicine, collaboration shaping COVID-19 paradigms. Continuous innovation, combined with an integrated adaptable approach, will be crucial effectively mitigating impact pandemics.

Language: Английский

Citations

0
Unravelling Insights into the Evolution and Management of SARS-CoV-2 DOI Creative Commons
Aganze Gloire-Aimé Mushebenge, Samuel Chima Ugbaja, Nonkululeko Avril Mbatha

et al.

BioMedInformatics, Journal Year: 2024, Volume and Issue: 4(1), P. 385 - 409

Published: Feb. 3, 2024

Worldwide, the COVID-19 pandemic, caused by brand-new coronavirus SARS-CoV-2, has claimed a sizable number of lives. The virus’ rapid spread and impact on every facet human existence necessitate continuous dynamic examination its biology management. Despite this urgency, does not currently have any particular antiviral treatments. As result, scientists are concentrating repurposing existing medications or creating ones. This comprehensive review seeks to provide an in-depth exploration our current understanding starting with analysis prevalence, pathology, evolutionary trends. In doing so, aims clarify complex network factors that contributed varying case fatality rates observed in different geographic areas. work, we explore world SARS-CoV-2 mutations their implications for vaccine efficacy therapeutic interventions. viral landscape pandemic poses significant challenge, leading investigate genetic foundations virus mechanisms underlying these alterations. Numerous hypotheses been proposed as developed, covering various subjects like selection pressures driving mutation, possibility escape, consequences clinical therapy. Furthermore, will shed light trials investigating novel medicines development, including promising field drug repurposing, providing window into changing treatment approaches. study provides compiling huge evolving body knowledge highlighting complexities public health, igniting additional investigation control unprecedented global health disaster.

Language: Английский

Citations

2
Pathogenesis of COVID19 and the applications of US FDA-approved repurposed antiviral drugs to combat SARS-CoV-2 in Saudi Arabia: A recent update by review of literature DOI Creative Commons
Almonther Abdullah Hershan

Saudi Journal of Biological Sciences, Journal Year: 2024, Volume and Issue: 31(7), P. 104023 - 104023

Published: May 11, 2024

Still, there is no cure for the highly contagious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-caused disease 2019 (COVID19). The COVID19 pandemic caused health emergencies which resulted in enormous medical and financial consequences worldwide including Saudi Arabia. Arabia largest Arab country of Middle East. urban setting makes it vulnerable towards SARS-CoV-2 (SCV-2). Religious areas this are visited by millions pilgrims every year Umrah Hajj pilgrimage, contributes to potential epidemic risk. throws various challenges healthcare professionals choose right drugs or therapy clinical settings because lack availability newer drugs. Current drug development discovery an expensive, complex, long process, involves a high failure rate trials. While repurposing United States Food Drug Administration (US FDA)-approved antiviral offers numerous benefits complete pharmacokinetic safety profiles, significantly shorten cycles reduce costs. A range repurposed US FDA-approved ribavirin, lopinavir/ritonavir combination, oseltamivir, darunavir, remdesivir, nirmatrelvir/ritonavir molnupiravir showed encouraging results trials treatment. In article, several COVID19-related discussions have been provided emerging variants concern of, pathogenesis, scenario Arabia, strategies against SCV-2, as well FDA‐approved that might be considered combat SCV-2 Moreover, context management along with its limitations future perspectives summarized.

Language: Английский

Citations

2